Results 91 to 100 of about 7,539 (166)

Unsupervised machine learning identifies biomarkers of disease progression in post-kala-azar dermal leishmaniasis in Sudan. [PDF]

PLoS Negl Trop Dis
Torres A, Younis BM, Tesema S, Solana JC, Moreno J, Martín-Galiano AJ, Musa AM, Alves F, Carrillo E.   +8 more
europepmc   +1 more source

Amphotericin B Deoxycholate Treatment of Post-Kala-Azar Dermal Leishmaniasis in India. [PDF]

Am J Trop Med Hyg
Sundar S, Chakravarty J, Singh J, Verma D, Agrawal N, Dinkar A.   +5 more
europepmc   +1 more source

Nationwide cross-sectional surveillance of Leishmania donovani in phlebotomine sand flies and its impact on national kala-azar elimination in India. [PDF]

Sci Rep
Shah HK, Fathima PA, Ajithlal PM, Kumar A, Rawani A, Thakur MS, Mohanty SS, Sarma DK, Pandey K, Kumar A, Rahi M, Saini P.   +11 more
europepmc   +1 more source

Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia. [PDF]

J Antimicrob Chemother
Palić S, Chu WY, Sundar S, Mondal D, Das P, Pandey K, Raja S, Rijal S, Roseboom IC, Hamadeh A, Malik PRV, Beijnen JH, Huitema ADR, Sjögren E, Alves F, Dorlo TPC.   +15 more
europepmc   +1 more source

Disease-Specific Differences in Pharmacokinetics of Paromomycin and Miltefosine Between Post-Kala-Azar Dermal Leishmaniasis and Visceral Leishmaniasis Patients in Eastern Africa. [PDF]

J Infect Dis
Chu WY, Verrest L, Younis BM, Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Monnerat S, Wasunna M, Roseboom IC, Solomos A, Huitema ADR, Alves F, Dorlo TPC.   +14 more
europepmc   +1 more source

VL-HIV co-infection with Leishmania containing skin lesions resembling para-kala-azar dermal leishmaniasis. [PDF]

PLoS Negl Trop Dis
Alves NO, Oshiro JA, Silva YC, Pacher GC, Casaril AE, Rizk YS, Uehara SNO, Paniago AMM, Andrade ILX, Arruda CCP, Oliveira AG.   +10 more
europepmc   +1 more source

Rising case-fatality rate of kala-azar (visceral leishmaniasis) in India: An unexpected challenge to the kala-azar elimination program?

Trop Parasitol
Mayilsamy M, Veeramanoharan R, Rajaiah P.   +2 more
europepmc   +1 more source

Monitoring the Long-Term Effectiveness of Miltefosine in Indian Post-Kala-Azar Dermal Leishmaniasis. [PDF]

Am J Trop Med Hyg
Roy S, Moulik S, Roy M, Ghosh MK, Chaudhuri SJ, Pandey DK, Jain S, Dagne DA, Chatterjee M.   +8 more
europepmc   +1 more source

A clinico-epidemiological study, assessing possible predictors of mortality and health-related quality of life for people living with visceral leishmaniasis - human immune virus (VL-HIV) co-infection in a high burden kala-azar endemic state of India: a descriptive cross-sectional study. [PDF]

BMC Infect Dis
Siddiqui NA, Pandey DK, Singh AK, Sinha SK, Ansari MZ, Kumar R, Pal B, Das VNR, Adhikary R, Jain S, Pandey K.   +10 more
europepmc   +1 more source

A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasis. [PDF]

Mol Ther Methods Clin Dev
Younis BM, Wiggins R, Khalil EAG, Osman M, Santoro F, Sonnati C, Keding A, Novedrati M, Montesi G, Noureldein A, Elmukashfi ETA, Mustafa AE, Alamin M, Saeed M, Salman K, Suliman AJ, Musa AEA, Layton AM, Lacey CJN, Kaye PM, Musa AM.   +20 more
europepmc   +1 more source